Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma.

Autor: Abou-Elkacem L; Department of Radiology, Molecular Imaging Program at Stanford, Stanford, California. kacem@stanford.edu., Wang H; Department of Radiology, Molecular Imaging Program at Stanford, Stanford, California., Chowdhury SM; Department of Radiology, Molecular Imaging Program at Stanford, Stanford, California., Kimura RH; Department of Radiology, Molecular Imaging Program at Stanford, Stanford, California., Bachawal SV; Department of Radiology, Molecular Imaging Program at Stanford, Stanford, California., Gambhir SS; Department of Radiology, Molecular Imaging Program at Stanford, Stanford, California., Tian L; Department of Health, Research and Policy, Stanford University, Stanford, California., Willmann JK; Department of Radiology, Molecular Imaging Program at Stanford, Stanford, California.
Jazyk: angličtina
Zdroj: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Apr 01; Vol. 24 (7), pp. 1574-1585. Date of Electronic Publication: 2018 Jan 04.
DOI: 10.1158/1078-0432.CCR-17-2057
Abstrakt: Purpose: To engineer a dual human and murine Thy1-binding single-chain-antibody ligand (Thy1-scFv) for contrast microbubble-enhanced ultrasound molecular imaging of pancreatic ductal adenocarcinoma (PDAC). Experimental Design: Thy1-scFv were engineered using yeast-surface-display techniques. Binding to soluble human and murine Thy1 and to Thy1-expressing cells was assessed by flow cytometry. Thy1-scFv was then attached to gas-filled microbubbles to create MB Thy1-scFv Thy1 binding of MB Thy1-scFv to Thy1-expressing cells was evaluated under flow shear stress conditions in flow-chamber experiments. MB scFv-scrambled and MB Non-targeted were used as negative controls. All microbubble types were tested in both orthotopic human PDAC xenografts and transgenic PDAC mice in vivo Results: Thy1-scFv had a K D of 3.4 ± 0.36 nmol/L for human and 9.2 ± 1.7 nmol/L for murine Thy1 and showed binding to both soluble and cellularly expressed Thy1. MB Thy1-scFv was attached to Thy1 with high affinity compared with negative control microbubbles ( P < 0.01) as assessed by flow cytometry. Similarly, flow-chamber studies showed significantly ( P < 0.01) higher binding of MB Thy1-scFv (3.0 ± 0.81 MB/cell) to Thy1-expressing cells than MB scFv-scrambled (0.57 ± 0.53) and MB Non-targeted (0.43 ± 0.53). In vivo ultrasound molecular imaging using MB Thy1-scFv demonstrated significantly higher signal ( P < 0.01) in both orthotopic (5.32 ± 1.59 a.u.) and transgenic PDAC (5.68 ± 2.5 a.u.) mice compared with chronic pancreatitis (0.84 ± 0.6 a.u.) and normal pancreas (0.67 ± 0.71 a.u.). Ex vivo immunofluorescence confirmed significantly ( P < 0.01) increased Thy1 expression in PDAC compared with chronic pancreatitis and normal pancreas tissue. Conclusions: A dual human and murine Thy1-binding scFv was designed to generate contrast microbubbles to allow PDAC detection with ultrasound. Clin Cancer Res; 24(7); 1574-85. ©2018 AACR .
(©2018 American Association for Cancer Research.)
Databáze: MEDLINE
Externí odkaz: